Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Purple Biotech Q3 EPS $(0.27)

Purple Biotech Q3 EPS $(0.27)

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

byBill Haddad

November 8, 2022

1 minute read

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.

News

BayFirst Financial To Discontinue Nationwide Network of Residential Mortgage LPOs

By Michael Horton

September 21, 5:01 PM

BayFirst Financial Corp. (NASDAQ:BAFN) (the "Company"), parent company of BayFirst National Bank (the "Bank"), today announced that due to the precipitous decline in mortgage volumes and the

BAFN

News
Tech

Warren Buffett-Backed BYD’s New Supercar Grooves On All 4 Wheels To Show Off Control System

By Anan Ashraf

April 11, 3:45 AM

Warren Buffett-backed BYD Co Ltd‘s (OTCPK: BYDDF) (OTCPK: BYDDY) Yangwang U9 EV can groove, and how! What Happened: BYD…

BYDDF

Bitcoin Spot ETFs See $48M Inflow As Ethereum Spot ETF Trading Draws Nearer

By Murtuza Merchant

May 31, 7:40 AM

Bitcoin (CRYPTO: BTC) continued their ongoing inflow streak lasting almost almost two weeks, as Ethereum ETF trading moved one step closer.

BTC

GlycoMimetics Announces New Uproleselan Clinical Data In Both Frontline Unfit And Treated Secondary Acute Myeloid Leukemia Presented At ASH Annual Meeting

By Benzinga Newsdesk

December 12, 8:10 AM

GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two

GLYC

Purple Biotech Q3 EPS $(0.27)

Related Posts

BayFirst Financial To Discontinue Nationwide Network of Residential Mortgage LPOs

Warren Buffett-Backed BYD’s New Supercar Grooves On All 4 Wheels To Show Off Control System

Bitcoin Spot ETFs See $48M Inflow As Ethereum Spot ETF Trading Draws Nearer

GlycoMimetics Announces New Uproleselan Clinical Data In Both Frontline Unfit And Treated Secondary Acute Myeloid Leukemia Presented At ASH Annual Meeting